Clinical trial · no report yet · Phase 3
RASolute 302
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- NCT06625320 ↗
- Active not recruiting
- Revolution Medicines, Inc.
- 234 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 146 | |
| YouTube | 42 | |
| Podcasts | 38 | |
| X videos | 8 |
The trial
ClinicalTrials.gov- Official title
- RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- RMC-6236; Gemcitabine; nab-paclitaxel; Irinotecan; Liposomal irinotecan; 5-fluorouracil; leucovorin; Oxaliplatin
- Arms
- RMC-6236 · Experimental
- Investigator's choice of standard of care therapy · Active comparator
- Enrollment
- 500
- Primary outcomes
- Progression free survival (PFS) in the RAS G12-mutant population
- Overall survival (OS) in the RAS G12-mutant population
- Sponsor
- Revolution Medicines, Inc.
- Start
- Oct 16, 2024
- Primary completion
- Jun 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06625320 · updated Jun 2, 2026
Publications
linked from the registry- O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM; RASolute 302 Trial Investigators. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026 Jul 23;395(4):325-337. doi: 10.1056/NEJMoa2605555. Epub 2026 May 31. PubMed 42223072